Exploring the Therapeutic Effects of Creatine Supplementation for Long COVID-19

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorUniversity of Calgary

About this trial

Individuals living with Long COVID often experiencing a degree of undue fatigue after physical or cognitive exertion secondary to the condition, timed post-exertional malaise 9PEM). This trial aims to explore the efficacy of creatine monohydrate in managing PEM

Eligibility criteria

Qualifiers

Experiencing symptoms at least 3 months after a COVID-19 diagnosis confirmed by positive polymerase chain reaction (PCR) test

Experiencing post-exertional malaise, as per the DePaul Symptom Questionnaire

Disqualifiers

Allergy or intolerance to creatine monohydrate or maltodextrin

Supplemented with creatine in the past eight weeks

orthopaedic injury or condition that would prevent exercise testing

change in medication related to Long COVID symptom management in the past month.

Trial design

Treatments tested in this trial

  • Creatine monohydrate

Treatment groups

24 Participants
are divided into 2 treatment groups

Locations

This trial has no locations

Sponsors and collaborators